SMT3 Suppressor of Mif Two 3 Homolog 4 (S. Cerevisiae) (SUMO4) (N-Term) antibody

Antigen: SMT3 Suppressor of Mif Two 3 Homolog 4 (S. Cerevisiae) (SUMO4)

Synonyms: IDDM5, SMT3H4, SUMO-4, dJ281H8.4

Binding Site: N-Term

Clonality: Polyclonal

Host: Rabbit

Reactivity: Please enquire

Application: Immunohistochemistry (IHC), Western Blotting (WB)

Catalog no.: ABIN350887

Additional Information

Alternative name: SUMO4 (Small ubiquitin-related modifier4)

UniProt: Q6EEV6

Immunogen: A synthetic peptide from the n-terminal of human SUMO4 (Small ubiquitin-related modifier4) conjugated to an immunogenic carrier protein was used as the immunogen.

Format: Lyophilized

Description: Function: Ubiquitin-like protein which can be covalently attached to target lysines as a monomer. Does not seem to be involved in protein degradation and may modulate protein subcellular localization, stability or activity. Upon oxidative stress, conjugates to various anti-oxidant enzymes, chaperones, and stress defense proteins. May also conjugate to NFKBIA, TFAP2A and FOS, negatively regulating their transcriptional activity, and to NR3C1, positively regulating its transcriptional activity. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I. Tissue specificity: Expressed mainly in adult and embryonic kidney. Expressed at various levels in immune tissues, with the highest expression in the lymph node and spleen. Post-translational modification: In contrast to SUMO1, SUMO2 and SUMO3, seems to be insensitive to sentrin-specific proteases due to the presence of Pro-90. This may impair processing to mature form and conjugation to substrates. Also known as: Small ubiquitin-related modifier 4, SUMO-4, Small ubiquitin-like protein 4, SUMO4, SMT3H4.

Specificity: Appears to be specific for SUMO4.

Application Details

Application Notes: IHC, WB. A dilution of 1: 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications.

Purity: whole serum

Storage: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Restrictions: For Research Use only

Publications

Mungall, Palmer, Sims et al.: "The DNA sequence and analysis of human chromosome 6." in: Nature, Vol. 425, Issue 6960, pp. 805-11, 2003 (PubMed).

Bohren, Nadkarni, Song et al.: "A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus." in: The Journal of biological chemistry, Vol. 279, Issue 26, pp. 27233-8, 2004 (PubMed).

Guo, Li, Zhang et al.: "A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes." in: Nature genetics, Vol. 36, Issue 8, pp. 837-41, 2004 (PubMed).

Smyth, Howson, Lowe et al.: "Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes." in: Nature genetics, Vol. 37, Issue 2, pp. 110-1; author reply 112-3, 2005 (PubMed).